Single Patient Death in Phase 1 BMS CAR-T Trial for Multiple Sclerosis Prompts Safety Review
A single fatal infection in an early BMS CAR-T study for MS illustrates the narrow therapeutic window when extending oncology-engineered cell therapies into autoimmune disease. Press-release reporting limits causal inference, and broader infection surveillance data from similar programs indicate this risk class requires dedicated mitigation strategies before larger trials.
Next steps likely include independent data monitoring committee review, possible dose de-escalation, and mandatory infection prophylaxis updates. Sponsors may expand exclusion criteria for patients with recent comorbidities to isolate therapy-attributable risk. Peer-reviewed publication of full safety tables from this and parallel trials remains essential before any pivotal program advances.
BMS: No additional treatment-related deaths reported in the MS cohort through 12-month follow-up data cutoff in Q2 2027.
Sources (3)
- [1]Bristol Myers Squibb Press Release on Phase 1 Trial Update(https://news.bms.com/news/details/2026/oct/23/bms-car-t-autoimmune-update)
- [2]NEJM Evidence: Early CAR-T Experience in Autoimmune Disease(https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400123)
- [3]FDA Cellular Therapy Safety Surveillance Report 2025(https://www.fda.gov/vaccines-blood-biologics/safety-surveillance)